Pharmaceutical Engineering of Lipid-Based Nanocarriers for Cancer Nanomedicines: From Doxorubicin to mRNA Platforms
ACS Biomaterials Science & Engineering · 10.08.2026 · 12 (8) · 3945-3984
DOI: 10.1021/acsbiomaterials.6c00618 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ACS Biomaterials Science & Engineering, online erschienen am 14.07.2026. Verfasst von Liam Gillman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Peptide Synthesis Facility Children's Medical Research Institute, Faculty of Medicine and Health, University of Sydney, Westmead, New South Wales2145…. Hauptthemen laut MEDLINE: Lipids, Neoplasms, RNA, Messenger, Doxorubicin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 351 Literaturangaben. Gefördert von: CMRI, Peptide Synthesis Facility, Children's Medical Research Institute, Faculty of Medicine and Health, University of Sydney.
Abstract (Originalsprache)
Designing therapeutic payloads to deliver drug molecules to the desired target site is challenging and requires effective, stable, and safe delivery systems in cancer therapy. Lipid-based nanocarriers have gained substantial interest in preclinical and clinical studies in anticancer drugs, leveraging their potential for drug delivery over the last few decades. While lipid-based nanocarrier technology has achieved some commercial success in different therapeutics and vaccines, challenges persist in their design, development, and quality control in large-scale manufacturing, most notably a lack of robust and scalable lipid-based nanocarrier synthesis and formulation for chemotherapy. To overcome these limitations, it is crucial to understand the role of lipids and other constituents that are utilized in lipid-based nanocarrier synthesis. Along with the compositions of lipid-based nanocarriers, their preparation methods also play a critical role. The structural design of lipid-based nanocarriers aims to impart the desired physicochemical properties, stability, bioavailability, safety, and efficacy of the drug-loaded lipid-based nanocarriers. Initially, this review provides a brief overview of the classification of lipids and other essential components used in the preparation of lipid-based nanocarriers. We then examine critical formulation parameters, including composition ratios, physicochemical characteristics, and preparation methods. We also include the recent progress of cancer nanomedicine and clinical trials, regulatory approval, and future direction to improve the delivery efficiency of lipid-based nanocarriers in cancer nanomedicine. Finally, we summarize the formulation of five distinct types of lipid-based nanocarriers employed for anticancer drug delivery and draw a connection between these formulations and the development of mRNA-based lipid nanoparticles (LNPs).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Peptide Synthesis Facility Children's Medical Research Institute, Faculty of Medicine and Health, University of Sydney, Westmead, New South Wales2145, Australia.
- Biomedical Proteomics Facility, Children's Medical Research Institute, Faculty of Medicine and Health, University of Sydney, Westmead, New South Wales2145, Australia.
- Gene Therapy Research Unit, Children's Medical Research Institute, Faculty of Medicine and Health, The University of Sydney and The Sydney Children's Hospitals Network, Westmead, New South Wales2145, Australia.
- School of Chemistry, University of New South Wales, Sydney, New South Wales2052, Australia.
ORCID-Profile: Md Musfizur Hassan
Förderung
- CMRI
- Peptide Synthesis Facility, Children's Medical Research Institute, Faculty of Medicine and Health, University of Sydney
Zitieren
APA
Gillman, L., Suleski, D., Graham, M. E., Ginn, S. L., & Hassan, M. M. (2026). Pharmaceutical Engineering of Lipid-Based Nanocarriers for Cancer Nanomedicines: From Doxorubicin to mRNA Platforms. ACS Biomaterials Science & Engineering, 12(8), 3945-3984. https://doi.org/10.1021/acsbiomaterials.6c00618
Vancouver
Gillman L, Suleski D, Graham ME, Ginn SL, Hassan MM. Pharmaceutical Engineering of Lipid-Based Nanocarriers for Cancer Nanomedicines: From Doxorubicin to mRNA Platforms. ACS Biomaterials Science & Engineering. 2026;12(8):3945-3984. doi:10.1021/acsbiomaterials.6c00618
BibTeX
@article{Gillman2026,
author = {Gillman, Liam and Suleski, Djordji and Graham, Mark E and Ginn, Samantha L and Hassan, Md Musfizur},
title = {Pharmaceutical Engineering of Lipid-Based Nanocarriers for Cancer Nanomedicines: From Doxorubicin to mRNA Platforms},
journal = {ACS Biomaterials Science & Engineering},
year = {2026},
volume = {12},
number = {8},
pages = {3945--3984},
doi = {10.1021/acsbiomaterials.6c00618}
}
EUVIMED